Implementación de un laboratorio de nivel de bioseguridad 2 para diagnóstico molecular de SARS-COV-2 en Puerto Iguazú, Misiones / Implementation of a biosafety level 2 laboratory for molecular diagnosis of SARS-COV-2 in Puerto Iguazú, Misiones

INTRODUCCIÓN: La pandemia de COVID-19 ha creado desafíos sin precedentes para los laboratorios de todo el mundo. Los gobiernos nacionales y subnacionales se vieron en la necesidad imperiosa de adaptar instituciones para la detección de SARS-CoV-2 en respuesta a la emergencia sanitaria declarada en 2020. Con el objetivo de aumentar la capacidad de diagnóstico en la provincia de Misiones, se implementó un laboratorio de diagnóstico de excelencia dentro del Instituto Misionero de Biodiversidad. Este artículo comparte los pasos realizados y los desafíos enfrentados, con el fin de que sirva de guía a otras instituciones. MÉTODOS: Las etapas para establecer el laboratorio fueron: adquisición de equipamientos/reactivos, adaptación/renovación del laboratorio, incorporación y capacitación del recurso humano, establecimiento de buenas prácticas y bioseguridad, selección de la metodología de extracción y detección, implementación de controles de calidad y habilitación. RESULTADOS: Desde su habilitación el Laboratorio de Análisis Integral procesó 1186 muestras biológicas de casos sospechosos de COVID-19 y se convirtió así en el segundo laboratorio de referencia provincial. DISCUSIÓN: La eficiente articulación entre el Instituto Misionero de Biodiversidad y el Ministerio de Salud de Misiones logró la rápida implementación de este laboratorio de alta complejidad en una región de importancia epidemiológica.

Implementation of a biosafety level 2 laboratory for molecular diagnosis of SARS-CoV-2 in Puerto Iguazú, Misiones / Implementación de un laboratorio de nivel de bioseguridad 2 para diagnóstico molecular de sars-cov-2 en puerto iguazú, misiones

RESUMEN INTRODUCCIÓN: La pandemia de COVID-19 ha creado desafíos sin precedentes para los laboratorios de todo el mundo. Los gobiernos nacionales y subnacionales se vieron en la necesidad imperiosa de adaptar instituciones para la detección de SARS-CoV-2 en respuesta a la emergencia sanitaria declarada en 2020. Con el objetivo de aumentar la capacidad de diagnóstico en la provincia de Misiones, se implementó un laboratorio de diagnóstico de excelencia dentro del Instituto Misionero de Biodiversidad. Este artículo comparte los pasos realizados y los desafíos enfrentados, con el fin de que sirva de guía a otras instituciones. MÉTODOS: Las etapas para establecer el laboratorio fueron: adquisición de equipamientos/reactivos, adaptación/renovación del laboratorio, incorporación y capacitación del recurso humano, establecimiento de buenas prácticas y bioseguridad, selección de la metodología de extracción y detección, implementación de controles de calidad y habilitación. RESULTADOS: Desde su habilitación el Laboratorio de Análisis Integral procesó 1186 muestras biológicas de casos sospechosos de COVID-19 y se convirtió así en el segundo laboratorio de referencia provincial. DISCUSIÓN: La eficiente articulación entre el Instituto Misionero de Biodiversidad y el Ministerio de Salud de Misiones logró la rápida implementación de este laboratorio de alta complejidad en una región de importancia epidemiológica.

ABSTRACT INTRODUCTION: The COVID-19 pandemic has created unprecedented challenges for laboratories around the world. National and subnational governments faced the urgent need to adapt institutions for the detection of SARS-CoV-2 in response to the health emergency declared in 2020. With the aim of increasing diagnostic capacity in the province of Misiones, a diagnostic laboratory of excellence was established within the "Instituto Misionero de Biodiversidad". This article shares the steps taken and the challenges faced, in order to serve as a guide to other institutions. METHODS: The stages to establish the laboratory were: acquisition of equipment/reagents, adaptation/ renovation of the laboratory, incorporation and training of human resources, establishment of good practices and biosafety, selection of the extraction and detection methodology, implementation of quality controls and authorization. RESULTS: Since its authorization, the "Laboratorio de Análisis Integral" has processed 1186 biological samples from suspected cases of COVID-19, becoming the second reference laboratory in Misiones. DISCUSSION: The efficient articulation between the "Instituto Misionero de Biodiversidad" and the provincial Ministry of Health achieved the rapid implementation of this high complexity laboratory in a region of epidemiological importance.

Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.

Allergic rhinitis is one of the most common clinical conditions in children; however, data regarding the safety of antihistamines in children with seasonal allergic rhinitis are limiting. To evaluate the safety and efficacy of fexofenadine in children with seasonal allergic rhinitis, data were pooled from three, double-blind, randomized, placebo-controlled, parallel-group, 2-week trials in children (6-11 year) with seasonal allergic rhinitis. All studies assessed fexofenadine HCl 30 mg b.i.d.; two studies included fexofenadine HCl at 15 and 60 mg b.i.d. Patients (and investigators) reported any adverse events during the trial. Physical examinations, including measurements of vital signs and laboratory tests, were performed. Efficacy assessments (total symptom score and individual symptom scores) were evaluated. Exposure to fexofenadine HCl 30 mg b.i.d. and to any fexofenadine dose exceeded 10,000 and 17,000 patient days, respectively. Incidences of adverse events, and discontinuations because of adverse events, were low and similar across treatment groups. In the placebo group, 24.4% of subjects reported adverse events compared with 24.1% for fexofenadine HCl 30 mg b.i.d., and 28.4% for all fexofenadine-treated groups. The most common adverse event overall was headache (4.3% placebo; 5.8% fexofenadine HCl 30 mg b.i.d.; and 7.2% any fexofenadine doses). Treatment-related adverse events were similar across treatment groups with no sedative effects. Fexofenadine HCl 30 mg b.i.d. was significantly superior to placebo in reducing the total symptom score and all individual seasonal allergic rhinitis symptoms, including nasal congestion (p < 0.05). Fexofenadine, at doses of up to 60 mg b.i.d., is safe and non-sedating, and fexofenadine HCl 30 mg b.i.d. effectively reduces all seasonal allergic rhinitis symptoms in children aged 6-11 years.

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis.

BACKGROUND: This is the first prospective, randomized, double-blind, placebo-controlled study showing statistical improvement of an H(1)-antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. OBJECTIVE: This randomized, placebo-controlled, parallel-group, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. METHODS: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (+/-1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point. RESULTS: Fexofenadine was significantly superior to placebo in the primary efficacy analysis (P